Tevogen Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Tevogen Inc. disclosed new Nasdaq non-compliance notices for both minimum market value of listed securities ($50M) and market value of publicly held shares ($15M), received in April 2026, compounding an existing material weakness in internal controls over financial reporting. The company remains pre-revenue with a clinical-stage pipeline (TVGN 489) and faces a 180-day compliance window with no assurance of remediation, raising going-concern and delisting risk.
Red Flags Detected (4)
Dual Nasdaq notifications of non-compliance with $50M market value of listed securities (MVLS) and $15M market value of publicly held shares (MVPHS) requirements
Material weakness in internal control over financial reporting persists from prior Annual Report and continues to render disclosure controls not effective
No material legal proceedings currently pending, but company is clinical-stage with no approved products or revenue-generating operations disclosed
1 more red flag detected
Key Takeaways
Company faces imminent Nasdaq delisting risk on two separate market value thresholds simultaneously
Internal control material weakness remains unresolved, indicating persistent governance/financial reporting risk
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.